CY1110055T1 - Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του πολλαπλου μυελωματος - Google Patents

Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του πολλαπλου μυελωματος

Info

Publication number
CY1110055T1
CY1110055T1 CY20081101395T CY081101395T CY1110055T1 CY 1110055 T1 CY1110055 T1 CY 1110055T1 CY 20081101395 T CY20081101395 T CY 20081101395T CY 081101395 T CY081101395 T CY 081101395T CY 1110055 T1 CY1110055 T1 CY 1110055T1
Authority
CY
Cyprus
Prior art keywords
treatment
arsenic trioxide
pharmaceutical compositions
compositions containing
multiple myeloma
Prior art date
Application number
CY20081101395T
Other languages
English (en)
Inventor
Ralph M Ellison
Fred H Mermelstein
Original Assignee
Polarx Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polarx Biopharmaceuticals, Inc. filed Critical Polarx Biopharmaceuticals, Inc.
Publication of CY1110055T1 publication Critical patent/CY1110055T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η εφεύρεση αναφέρεται στη χρήση των ενώσεων αρσενικού για την θεραπεία μιας ποικιλίας νεοπλαστικών ασθενειών συγκεκριμένα του πολλαπλού μυελώματος. Περαιτέρω, οι ενώσεις αρσενικού μπορούν να χρησιμοποιηθούν για να θεραπεύσουν τις μεταστατικές νεοπλαστικές ασθένειες.
CY20081101395T 1997-10-15 2008-12-02 Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του πολλαπλου μυελωματος CY1110055T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6237597P 1997-10-15 1997-10-15
EP03019594A EP1378240B1 (en) 1997-10-15 1998-10-15 Pharmaceutical compositions comprising arsenic trioxide for the treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
CY1110055T1 true CY1110055T1 (el) 2015-01-14

Family

ID=22042073

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20081101031T CY1108363T1 (el) 1997-10-15 2008-09-24 Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του μη-hodgkin λεμφωματος
CY20081101395T CY1110055T1 (el) 1997-10-15 2008-12-02 Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του πολλαπλου μυελωματος
CY20081101430T CY1110057T1 (el) 1997-10-15 2008-12-10 Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια ενος ογκου του κεντρικου νευρικου συστηματος
CY20111100361T CY1111379T1 (el) 1997-10-15 2011-04-05 Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση πρωτογενων και μεταστατικων-νεοπλασματικων ασθενειων με τη χρηση τριοξειδιου του αρσενικου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20081101031T CY1108363T1 (el) 1997-10-15 2008-09-24 Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του μη-hodgkin λεμφωματος

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20081101430T CY1110057T1 (el) 1997-10-15 2008-12-10 Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια ενος ογκου του κεντρικου νευρικου συστηματος
CY20111100361T CY1111379T1 (el) 1997-10-15 2011-04-05 Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση πρωτογενων και μεταστατικων-νεοπλασματικων ασθενειων με τη χρηση τριοξειδιου του αρσενικου

Country Status (21)

Country Link
US (9) US6875451B2 (el)
EP (9) EP1466607A1 (el)
JP (1) JP2001519366A (el)
KR (1) KR20010015755A (el)
CN (1) CN1282218A (el)
AT (4) ATE399560T1 (el)
AU (1) AU751932B2 (el)
BR (1) BR9813085A (el)
CA (1) CA2307208A1 (el)
CY (4) CY1108363T1 (el)
DE (4) DE69842094D1 (el)
DK (4) DK1378240T3 (el)
ES (4) ES2358624T3 (el)
HK (3) HK1061198A1 (el)
IL (1) IL135620A0 (el)
NO (1) NO20001977L (el)
NZ (1) NZ503973A (el)
PL (1) PL339909A1 (el)
PT (4) PT2018858E (el)
TR (1) TR200001959T2 (el)
WO (1) WO1999018798A1 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID25622A (id) * 1997-11-10 2000-10-19 Sloan Kettering Inst Cancer Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
WO2003003855A1 (de) * 2001-07-05 2003-01-16 Luedke Hans-Werner Nahrungsergänzungsprodukt oder arzneimittel gegen bestimmte mangelzustände und hirnfunktionsstörungen
AUPR874601A0 (en) * 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
KR20030058019A (ko) * 2001-12-29 2003-07-07 한국원자력연구소 삼산화비소(Ａｓ₂Ｏ₃)를 유효 성분으로 포함하는 방사선치료증진제
US6911471B2 (en) * 2002-01-07 2005-06-28 The Texas A&M University System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
MXPA04009898A (es) * 2002-04-10 2005-06-20 Korea Microbiological Lab Ltd Composicion farmaceutica que comprende arsenita para el tratamiento de tumores malignos.
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
US8394422B2 (en) * 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
KR100492940B1 (ko) * 2002-05-27 2005-06-02 김종배 항종양활성 증진용 조성물
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US8906422B2 (en) * 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
CA2504935C (en) 2002-11-07 2012-04-10 Unisearch Limited Induction of the mitochondrial permeability transition
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005062810A2 (en) * 2003-12-18 2005-07-14 Mediscovery, Llc Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide
AU2005219876A1 (en) * 2004-03-01 2005-09-15 Peptimmune, Inc. Methods and compositions for treatment of autoimmune diseases
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm
US20050208149A1 (en) * 2004-03-18 2005-09-22 Tty Biopharm Limited Company Use of arsenic-containing pharmaceutical composition in combination with radiation therapy for cancer treatment
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060003966A1 (en) 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
EP1789107B1 (en) * 2004-08-30 2009-05-27 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
US8258181B2 (en) 2005-03-23 2012-09-04 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
AU2006285329B2 (en) * 2005-07-29 2012-10-04 Solasia Pharma K.K. Compounds and methods for the treatment of cancer
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
WO2007028154A2 (en) * 2005-09-02 2007-03-08 Northwestern University Encapsulated arsenic drugs
US8784899B2 (en) * 2005-10-04 2014-07-22 Samuel Waxman Cancer Research Foundation Compositions and methods for cancer treatment
US20080233207A1 (en) * 2006-01-04 2008-09-25 Sheptovitsky Yelena G Injectable and Infusable Mercury Compositions and Methods for Treating Cancer
ITMI20060480A1 (it) * 2006-03-16 2007-09-17 Solvay Solexis Spa Usom di perfluoropolimeri nella dtermibnazione della costante di legame recettore-ligando
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
CN101595115B (zh) 2006-11-01 2012-07-18 新南部创新有限公司 有机-氧化砷化合物及其用途
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
BRPI0806365B8 (pt) * 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
JP5730575B2 (ja) 2007-10-01 2015-06-10 リクスト・バイオテクノロジー，インコーポレイテッド Ｈｄａｃ阻害剤
WO2009061373A1 (en) * 2007-11-02 2009-05-14 Ziopharm Oncology, Inc. Combination therapy with organic arsenicals
CN101874034A (zh) * 2007-12-12 2010-10-27 Zio医药肿瘤学公司 用于治疗癌症的化合物和方法
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010014220A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010014141A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
CN104800828A (zh) 2008-08-20 2015-07-29 日本苏爱康制药有限公司 用于治疗癌症的有机砷化合物和方法
KR101100786B1 (ko) * 2008-12-16 2011-12-29 (주)천지산 암에 대한 방사선 치료 증진용 조성물
JP5710619B2 (ja) * 2009-09-10 2015-04-30 コミノックス・インコーポレイテッド 癌幹細胞を標的とした薬剤耐性癌治療法
MX2012002922A (es) * 2009-09-18 2012-09-07 Kominox Inc Metodos para tratar tumores del cerebro.
US20120015023A1 (en) * 2010-04-15 2012-01-19 Antimisiaris Sophia G Treatment of tumors prostate with arsonoliposomes
WO2014152330A1 (en) * 2013-03-15 2014-09-25 Stc.Unm Arsenic-based treatment of cancers and inflammatory disorders
WO2014151317A1 (en) * 2013-03-15 2014-09-25 Rush University Medical Center Methods for treating cancer
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
FR3004949B1 (fr) * 2013-04-26 2016-02-05 Centre Nat Rech Scient Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale
US9700580B1 (en) 2016-06-14 2017-07-11 Marguerite Harning Method for cancer treatment
PE20191544A1 (es) 2016-12-01 2019-10-24 Eupharma Pty Ltd Composiciones de arsenico
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
WO2018209343A1 (en) * 2017-05-12 2018-11-15 Rajur Sharanappa Basappa Novel methods, compounds, and compositions: small molecule anticancer agents
WO2019234112A1 (en) 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
CN112675197A (zh) * 2021-01-22 2021-04-20 中山大学孙逸仙纪念医院 一种用于儿童Hedgehog信号通路驱动肿瘤的药物组合物
CN114028425A (zh) * 2021-09-24 2022-02-11 上海交通大学医学院附属新华医院 硫化砷及其与放疗联合在治疗横纹肌肉瘤上的应用
CN115634287A (zh) * 2022-09-30 2023-01-24 苏州系统医学研究所 一种基于砷化合物的肿瘤疫苗及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132275A (en) 1872-10-15 Improvement in medical compounds
US232807A (en) 1880-10-05 Herbert e
US3700498A (en) 1970-12-10 1972-10-24 Ibm Process for making electrophotographic plates
JPS5188620A (en) 1975-01-31 1976-08-03 Jintainokenkonoiji kotonigannitaishitekonoojusuru noshukuionekinoseizoho
DE3003635C2 (de) 1980-02-01 1985-07-11 Klöckner-Humboldt-Deutz AG, 5000 Köln Verfahren und Vorrichtung zur Entarsenierung arsenhaltiger Materialien
US4599305A (en) * 1984-07-16 1986-07-08 The Regents Of The University Of California Method and composition for detection of human chronic myelogenous leukemia
NL8502929A (nl) * 1985-10-25 1987-05-18 Tno Groep viii-overgangsmetaal-complexen, werkwijze voor het bereiden daarvan, werkwijze voor het bereiden van een geneesmiddel met toepassing van een dergelijke groep viii-overgangsmetaal-complex voor de behandeling van kanker, alsmede aldus verkregen gevormd geneesmiddel.
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
CN1061908A (zh) 1991-12-21 1992-06-17 江西省妇产医院 一种治癌药物的制造方法
CN1060935C (zh) 1992-05-31 2001-01-24 丛繁滋 用于癌病灶直接给药的砷制剂的制备方法
CN1044777C (zh) 1992-07-06 1999-08-25 杨世泽 癌痛止痛膏的配制方法
AU682007B2 (en) 1992-07-24 1997-09-18 Johns Hopkins University, The Use of inhibitors of fatty acid synthesis for treating cancer
FR2699820B3 (fr) * 1992-12-24 1995-03-10 Eric Pichot Traitement homéopathique préventif des dysmytoses (cancer, leucémie) et malformations ou mutations génétiques.
DE4317331A1 (de) * 1993-05-25 1994-12-01 Reischle Karl Georg Behandlung von Schädigungen des Immunsystems
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
DE69434093T2 (de) 1994-02-18 2006-03-09 Tamara Vasilievna Vorobieva Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
CN1119113A (zh) 1994-09-22 1996-03-27 衣永德 复方癌复康胶囊及制备方法
CN1122700A (zh) 1994-11-08 1996-05-22 付知中 一种治疗乳腺疾病、肿瘤疮毒的散剂及其制备方法
LV11667B (en) * 1995-08-14 1997-06-20 Tamara Vorobieva Remedy for renewal of disordered function of immunomodulation and cell tissue reproduction adjustors
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
US5748699A (en) * 1995-10-06 1998-05-05 Smith; Donald O. Apparatus for applying X-rays to an interior surface of a body cavity
CN1058620C (zh) 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
CN1052648C (zh) 1995-12-03 2000-05-24 唐书生 癌瘤消肿止痛膏
ID25622A (id) 1997-11-10 2000-10-19 Sloan Kettering Inst Cancer Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
ES2285251T3 (es) * 2002-09-24 2007-11-16 Novartis Ag Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos.
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm

Also Published As

Publication number Publication date
PT1391206E (pt) 2008-08-13
DK1391206T3 (da) 2008-09-01
JP2001519366A (ja) 2001-10-23
NZ503973A (en) 2001-09-28
NO20001977L (no) 2000-06-13
EP1621077A1 (en) 2006-02-01
US20050100611A1 (en) 2005-05-12
EP1391206A1 (en) 2004-02-25
NO20001977D0 (no) 2000-04-14
EP1022951A1 (en) 2000-08-02
EP2018858A1 (en) 2009-01-28
EP1466607A1 (en) 2004-10-13
HK1061198A1 (en) 2004-09-10
EP1391206B1 (en) 2008-07-02
ATE407683T1 (de) 2008-09-15
DK2018858T3 (da) 2013-01-07
US6875451B2 (en) 2005-04-05
CY1111379T1 (el) 2015-08-05
CY1110057T1 (el) 2015-01-14
EP1378240A2 (en) 2004-01-07
HK1085886A1 (en) 2006-09-08
DE69840006D1 (de) 2008-10-23
DE69840057D1 (de) 2008-11-06
PT2018858E (pt) 2011-03-24
US20020183385A1 (en) 2002-12-05
WO1999018798A1 (en) 1999-04-22
US20040197421A1 (en) 2004-10-07
ES2312701T3 (es) 2009-03-01
PL339909A1 (en) 2001-01-15
EP2018858B1 (en) 2011-01-05
AU751932B2 (en) 2002-08-29
DE69842094D1 (de) 2011-02-17
EP1374875A2 (en) 2004-01-02
US20040197420A1 (en) 2004-10-07
ES2313201T3 (es) 2009-03-01
US20050191367A1 (en) 2005-09-01
US7179493B2 (en) 2007-02-20
CN1282218A (zh) 2001-01-31
US7163703B2 (en) 2007-01-16
EP1378240B1 (en) 2008-09-10
ATE399560T1 (de) 2008-07-15
PT1621077E (pt) 2008-11-04
DK1378240T3 (da) 2008-12-08
HK1061199A1 (en) 2004-09-10
EP1621077B1 (en) 2008-09-24
IL135620A0 (en) 2001-05-20
ES2358624T3 (es) 2011-05-12
EP1022951A4 (en) 2002-06-19
US20040096518A1 (en) 2004-05-20
ATE409043T1 (de) 2008-10-15
PT1378240E (pt) 2008-11-14
ATE493979T1 (de) 2011-01-15
AU1089399A (en) 1999-05-03
BR9813085A (pt) 2000-08-22
DK1621077T3 (da) 2009-01-26
US20040161475A1 (en) 2004-08-19
EP1419778A1 (en) 2004-05-19
DE69839682D1 (de) 2008-08-14
ES2309258T3 (es) 2008-12-16
US7132116B2 (en) 2006-11-07
TR200001959T2 (tr) 2000-11-21
US20040115283A1 (en) 2004-06-17
KR20010015755A (ko) 2001-02-26
US20040047916A1 (en) 2004-03-11
CA2307208A1 (en) 1999-04-22
US7205001B2 (en) 2007-04-17
EP1378241A1 (en) 2004-01-07
CY1108363T1 (el) 2014-02-12
EP1374875A3 (en) 2004-01-07
EP1378240A3 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
CY1110055T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του πολλαπλου μυελωματος
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
ATE265455T1 (de) Tetrahydropyridoverbindungen
IL97055A0 (en) Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives
BR0215689A (pt) Composição farmacêutica compreendendo arsênico para o tratamento de malignidade
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
EP0793499A4 (en) METHOD AND MEANS FOR REDUCING TUMOR DEVELOPMENT BY MEANS OF A COMBINATION OF A TAXAN COMPOUND AND A TELLUR AND / OR SELENIUM COMPOUND
MX9701832A (es) Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.